BioMarin's Gene Therapy Nears European Market After US Setback.

It's seen as cost-effective because current hemophilia treatments are expensive -- as much as $750,000 a year per person in the US -- and they're given to patients over a lifetime, BioMarin said. (Bloomberg) -- BioMarin Pharmaceutical Inc. expects European patients to begin receiving its gene therapy for a life-threatening blood-clotting disorder before the end of the year, raising the drugmaker's hopes it can succeed where rival Bluebird Bio Inc. faltered. [Extracted from the article]

Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)